Novo CEO pressed by Senate to chop rates of being overweight, diabetes medications CEO Lars Fruergaard Jørgensen told lawmakers the company would take into consideration new talks with insurers in regards to the record rates of Wegovy and copyright should they pledge to help keep the medicines on their formularies. https://label-the-figure-with-the17395.rimmablog.com/30106179/about-healthcare-news